Nonalcoholic fatty liver with a hepatic arterial buffer response strongly associated with future metabolic disease

Masashi Hirooka, Yohei Koizumi, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Atsushi Yukimoto, Yoshiko Nakamura, Yusuke Imai, Masanori Abe, Yoichi Hiasa – 27 July 2017 – A change in hepatic blood flow caused by the hepatic arterial buffer response (HABR) occurs as fatty liver disease progress. The aim of this longitudinal cohort study was to investigate whether fatty liver with the HABR induces metabolic disorders. In 2009 and 2010, 494 (89.5%) participants were enrolled. The median follow‐up duration was 5.0 (interquartile range, 3.9‐6.0) years.

L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Impact of Sustained Virologic Response with Direct‐Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 27 July 2017 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral treatment is not well documented. This study evaluated the impact of direct‐acting antiviral–induced SVR on all‐cause mortality and on incident hepatocellular carcinoma (HCC) in 15,059 hepatitis C virus–infected patients with advanced liver disease defined by a FIB‐4 >3.25. Overall, 1,067 patients did not achieve SVR (no SVR) and 13,992 patients achieved SVR.

Hepatocyte‐derived exosomes promote T follicular regulatory cell expansion during hepatitis C virus infection

Dustin A. Cobb, Ok‐Kyung Kim, Lucy Golden‐Mason, Hugo R. Rosen, Young S. Hahn – 27 July 2017 – Hepatitis C virus (HCV) is a global health concern that can cause severe liver disease, such as cirrhosis and hepatocellular carcinoma. Control of HCV requires vigorous T‐cell responses, yet CD4+ T cells in chronic HCV patients are dysfunctional. T follicular regulatory (Tfr) cells are a subset of regulatory T cells that suppress T follicular helper (Tfh) cells and the generation of high affinity antibody‐producing B cells.

A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Naoya Kanogawa, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Kazue Nagai, Tomoo Nakagawa, Takeshi Sugawara, Hideki Hanaoka, Fumihiko Kanai, Osamu Yokosuka – 26 July 2017 – This randomized, double‐blind, placebo‐controlled trial evaluated dexamethasone efficacy at preventing fever, anorexia, and nausea/vomiting, the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Profiling of the circadian metabolome in thioacetamide‐induced liver cirrhosis in mice

Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Isao Sakaida – 26 July 2017 – Liver cirrhosis can disturb circadian rhythms, decreasing patient quality of life. Changes in metabolic products in cirrhosis are poorly understood. We evaluated changes in liver metabolism products using a thioacetamide‐induced mouse model of liver cirrhosis exhibiting circadian rhythm disturbance.

Subscribe to